Sequenom, CombiMatrix Collaborate to Market NIPD Testing with CMA | GenomeWeb

NEW YORK (GenomeWeb News) – Sequenom and CombiMatrix today announced an agreement to market chromosomal microarray analysis testing services "to broaden and confirm the results of non-invasive prenatal testing" to doctors and patients.

Under the terms of the deal, the Sequenom Center for Molecular Medicine and CombiMatrix will promote the use of NIPD testing and CMA, as well as provide technical training to physicians. They also will provide counseling, educational, and support services to physicians and their patients, they said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.